Practice Apoptosis: When Partners Retire

Article

Kicking off the first in a series of podcasts, a noted healthcare consultant discusses how retirement can fracture a practice.

In today’s challenging environment, community oncology practices must devise new business models if they are to continue providing high quality care for patients while adequately compensating their physicians. Practices must also adapt to an environment in which professional-fee revenue plays an increasingly important role in reimbursing for care.

In short, busy community doctors need to create a sound business plan that complements the skills and needs of their partners. Building the right practice “chemistry” is tantamount to success. So, what happens when a partner, or two, decides to retire? In this podcast, noted healthcare consultant, Thomas A. Paivanas, discusses the realities, with the caveat, fortune favors a prepared mind.

Stay tuned for our next expert podcast: Martin Neltner talks about quality in cancer care, what it means to the busy practitioner as we move forward into our brave new world of healthcare…
 

           
 

Practice Apoptosis: When Partners Retire
Right mouse click and "Save As" to download

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.